EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology

Sharon P Shriver iD, Devon Adams iD, Brittany Avin McKelvey iD, Jeannine S McCune, Dale Miles iD, Victoria M Pratt iD, Kristine Ashcraft, Howard L McLeod iD, Hannah Williams iD, Mark E Fleury iD

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01748 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Sharon P Shriver und 9 weiteren Autor:innen. Beteiligte Einrichtung: ACS CAN, Washington, DC. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Precision Medicine. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics (PGx), the study of inherited genomic variation and drug response or safety, is a vital tool in precision medicine. In oncology, testing to identify PGx variants offers patients the opportunity for customized treatments that can minimize adverse effects and maximize the therapeutic benefits of drugs used for cancer treatment and supportive care. Because individuals of shared ancestry share specific genetic variants, PGx factors may contribute to outcome disparities across racial and ethnic categories when genetic ancestry is not taken into account or mischaracterized in PGx research, discovery, and application. Here, we examine how the current scientific understanding of the role of PGx in differential oncology safety and outcomes may be biased toward a greater understanding and more complete clinical implementation of PGx for individuals of European descent compared with other genetic ancestry groups. We discuss the implications of this bias for PGx discovery, access to care, drug labeling, and patient and provider understanding and use of PGx approaches. Testing for somatic genetic variants is now the standard of care in treatment of many solid tumors, but the integration of PGx into oncology care is still lacking despite demonstrated actionable findings from PGx testing, reduction in avoidable toxicity and death, and return on investment from testing. As the field of oncology is poised to expand and integrate germline genetic variant testing, it is vital that PGx discovery and application are equitable for all populations. Recommendations are introduced to address barriers to facilitate effective and equitable PGx application in cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingPrecision MedicineHumansPharmacogeneticsGenetic TestingMedical Oncology

Autor:innen und Institutionen

  • ACS CAN, Washington, DC.
  • Friends of Cancer Research, Washington, DC.
  • City of Hope/Beckman Research Institute Department of Hematologic Malignancies Translational Sciences, Duarte, CA.
  • Genentech, San Francisco, CA.
  • Agena Bioscience, San Diego, CA.
  • Invitae Corporation, San Francisco, CA.

ORCID-Profile: Sharon P Shriver, Devon Adams, Brittany Avin McKelvey, Dale Miles, Victoria M Pratt, Howard L McLeod, Hannah Williams, Mark E Fleury

Zitieren

APA

Shriver, S. P., Adams, D., McKelvey, B. A., McCune, J. S., Miles, D., Pratt, V. M., Ashcraft, K., McLeod, H. L., Williams, H., & Fleury, M. E. (2024). Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01748

Vancouver

Shriver SP, Adams D, McKelvey BA, McCune JS, Miles D, Pratt VM, et al. Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01748

BibTeX
@article{Shriver2024,
  author = {Shriver, Sharon P and Adams, Devon and McKelvey, Brittany Avin and McCune, Jeannine S and Miles, Dale and Pratt, Victoria M and Ashcraft, Kristine and McLeod, Howard L and Williams, Hannah and Fleury, Mark E},
  title = {Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01748}
}
Kostenlos starten →